Zobrazeno 1 - 10
of 37
pro vyhledávání: '"I. Añón Oñate"'
Autor:
N. Mena-Vázquez, C. M. Romero-Barco, M. Rojas-Giménez, R. Redondo, I. Ureña, I. Añón Oñate, P. Morales-Garrido, L. Pérez Albaladejo, M. Velloso Feijoo, M. D. C. Ordoñez Cañizares, S. Manrique Arija
Publikováno v:
Annals of the Rheumatic Diseases. 81:739-740
BackgroundInterstitial lung disease (ILD) is a common condition in patients with connective tissue disease (CTD). It is associated with increased morbidity and mortality. Rituximab (RTX) has been approved for treatment of RA and some recent retrospec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d0643fae23397a12271bfe4937994253
https://doi.org/10.1136/annrheumdis-2022-eular.3014
https://doi.org/10.1136/annrheumdis-2022-eular.3014
Publikováno v:
Annals of the Rheumatic Diseases. 81:1584.2-1585
BackgroundNowadays, non-alcoholic fatty liver is the most common hepatic disease.In patients with psoriatic arthritis with metabolic syndrome or obesity, there is a state of inflammation that produces the existence of a replacement of normal hepatic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b6e25113ceed54697f047d6bd14857cf
https://doi.org/10.1136/annrheumdis-2022-eular.3566
https://doi.org/10.1136/annrheumdis-2022-eular.3566
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
M. J. Pérez Galán, C. Lopez-Pedrera, G. G. Ignacio, A. M. Patiño-Trives, D. Ruiz, E. Collantes Estevez, A. Escudero Contreras, Carmen Torres-Granados, N. Barbarroja Puerto, M. D. López Montilla, I. Añón Oñate, I. Arias de la Rosa, M. D. C. Abalos-Aguilera, María Luque-Tévar
Publikováno v:
Annals of the Rheumatic Diseases. 79:424-425
Background:The presence of cardiovascular disease in psoriatic arthritis (PsA) is of particular concern, as it is considered the leading cause of mortality in PsA. Thus, it is essential to recognize those appropriate therapies that could target this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eaf24d39c600cc1c831f44801d014b13
https://doi.org/10.1136/annrheumdis-2020-eular.5447
https://doi.org/10.1136/annrheumdis-2020-eular.5447
Autor:
C. Lopez-Pedrera, D. Ruiz, Cristóbal Román-Rodríguez, María Luque-Tévar, A. Escudero Contreras, N. Barbarroja Puerto, A. M. Patiño-Trives, Clementina López-Medina, C. Perez-Sanchez, I. Arias de la Rosa, M. D. López Montilla, I. Gómez García, M. L. Ladehesa Pineda, E. Collantes Estevez, I. Añón Oñate, M. D. C. Abalos-Aguilera, M. J. Pérez Galán
Publikováno v:
Annals of the Rheumatic Diseases. 80:1317.2-1318
Background:Psoriatic Arthritis (PsA) displays increased traditional cardiovascular (CV) risk factors, such as insulin resistance (IR), metabolic syndrome or obesity. Thus, it is an urgent need to treat and manage these cardiometabolic comorbidities a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1015e85bc1e51e8418db609f321ef25a
https://doi.org/10.1136/annrheumdis-2021-eular.2956
https://doi.org/10.1136/annrheumdis-2021-eular.2956
Autor:
I. Añón Oñate, Marta Rojas-Giménez, S. Manrique Arija, Francisco Javier Godoy-Navarrete, B. Panero Lamothe, María Isabel Padin-Martín, F. G. Jiménez-Núñez, María Carmen Aguilar-Hurtado, C.M. Romero-Barco, L. Pérez Albaladejo, Antonio Fernández-Nebro, R. Ortega Castro, R. Redondo, ML Velloso Feijoo, F. Espildora, I. Ureña, Natalia Mena-Vázquez
Publikováno v:
Annals of the Rheumatic Diseases. 80:323.1-323
Objectives:To analyze the effect of disease-modifying antirheumatic drugs (DMARDs) and identify risk factors associated with disease progression and mortality in patients with rheumatoid arthritis associated with interstitial lung disease (RA-ILD).Me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7928ac203d38ceb4cd03eeb70181893e
https://doi.org/10.1136/annrheumdis-2021-eular.1090
https://doi.org/10.1136/annrheumdis-2021-eular.1090
Publikováno v:
Annals of the Rheumatic Diseases. 79:1661.1-1662
Background:Apremilast (APR) is a phosphodiesterase 4 Inhibitor. APR has been demonstrated to be an effective and safe therapy in the treatment of active psoriatic arthritis (PsA) and psoriasis in patients who were intolerant of or unresponsive to syn
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64887dda3e34f8e3a79fd67dda5cc6ad
https://doi.org/10.1136/annrheumdis-2020-eular.1237
https://doi.org/10.1136/annrheumdis-2020-eular.1237
Autor:
L. Pérez Albaladejo, Antonio Fernández-Nebro, Natalia Mena-Vázquez, I. Añón Oñate, C.M. Romero-Barco, Francisco Javier Godoy-Navarrete
Publikováno v:
Annals of the Rheumatic Diseases. 79:25.2-26
Background:Objectives:To analyze the effect of disease-modifying antirheumatic drugs (DMARDs) on the outcome of interstitial lung disease secondary to rheumatoid arthritis (ILD-RA).Methods:We performed a multicenter, prospective, observational study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed3d1b68883fe696f5235fd5471e5579
https://doi.org/10.1136/annrheumdis-2020-eular.2893
https://doi.org/10.1136/annrheumdis-2020-eular.2893
Autor:
R. Cáliz Cáliz, I. Añón Oñate, J.M. Andreu Ubero, L. Pérez Albaladejo, M. Á. Ferrer González, I. Notario Ferreira, A. García Sánchez, S. Quirosa Flores, M.C. Ramírez Barberena, M. Ramírez de la Torre
Publikováno v:
SLE, Sjögren’s and APS – clinical aspects (other than treatment).
Background The Antiphospholipid Syndrome (APS) and Thrombophilia predominantly affect women of fertile age, so their pregnancies should be considered high obstetric risk. These pregnant women need close monitoring in a multidisciplinary unit. Objecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b3c0b4c8e5083a7bd54865084b3fa95
https://doi.org/10.1136/annrheumdis-2018-eular.4912
https://doi.org/10.1136/annrheumdis-2018-eular.4912